United Therapeutics Corporation logo

United Therapeutics Corporation (UTHR)

Market Closed
12 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
545. 96
+0.56
+0.1027%
$
23.17B Market Cap
11.96 P/E Ratio
- Div Yield
451,800 Volume
24.04 Eps
$ 545.4
Previous Close
Add Transaction
Day Range
536.39 547.59
Year Range
272.12 609.35
Want to track UTHR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Here's Why United Therapeutics (UTHR) is a Strong Value Stock

Here's Why United Therapeutics (UTHR) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
UTHR vs. CTLT: Which Stock Is the Better Value Option?

UTHR vs. CTLT: Which Stock Is the Better Value Option?

Investors interested in Medical - Drugs stocks are likely familiar with United Therapeutics (UTHR) and Catalent (CTLT). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks | 1 year ago
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term

Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
UTHR vs. CTLT: Which Stock Should Value Investors Buy Now?

UTHR vs. CTLT: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Catalent (CTLT). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks | 1 year ago
Is United Therapeutics (UTHR) a Solid Growth Stock? 3 Reasons to Think "Yes"

Is United Therapeutics (UTHR) a Solid Growth Stock? 3 Reasons to Think "Yes"

United Therapeutics (UTHR) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks | 1 year ago
What Makes United Therapeutics (UTHR) a Strong Momentum Stock: Buy Now?

What Makes United Therapeutics (UTHR) a Strong Momentum Stock: Buy Now?

Does United Therapeutics (UTHR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks | 1 year ago
UTHR or CTLT: Which Is the Better Value Stock Right Now?

UTHR or CTLT: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Catalent (CTLT). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks | 1 year ago
United Therapeutics Corporation (UTHR) Hit a 52 Week High, Can the Run Continue?

United Therapeutics Corporation (UTHR) Hit a 52 Week High, Can the Run Continue?

United Therapeutics (UTHR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks | 1 year ago
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term

Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term

Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
United Therapeutics (UTHR) Completes Enrolment in IPF Study

United Therapeutics (UTHR) Completes Enrolment in IPF Study

United Therapeutics' (UTHR) late-stage study is evaluating Tyvaso inhalation solution in IPF patients living outside the United States and Canada.

Zacks | 1 year ago
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?

Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?

United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks | 1 year ago
Loading...
Load More